Abstract
UC781, a thiocarboxanilide nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT), inhibited RT DNA polymerase activity in vitro with marked potency. Significant inhibition was noted at a 1:1 molar ratio of UC871 to RT, characteristic of a tight-binding inhibitor. Infectivity of the HIV-1(IIIB) laboratory strain was eliminated in a concentration-dependent manner following short exposure of isolated virion particles to UC781. Neither nevirapine nor certain other carboxanilide nonnucleoside inhibitors were effective in this manner. Endogenous reverse transcription in UC781-treated virus particles was markedly reduced. Treatment of chronically HIV-1-infected H9 cells with UC781 did not alter virus production, but the infectivity of the virus produced by the cells during drug exposure was markedly reduced. Moreover, the infectivity of nascent virus produced by the UC781-treated H9 cells after removal of exogenous drug was dramatically attenuated. Similarly, pretreatment of peripheral blood lymphocytes isolated from HIV-infected patients abolished the infectivity of virus produced by these cells after removal of exogenous drug, as measured by coculture experiments with uninfected cord blood mononuclear cells, indicating the utility of UC781 against a variety of clinical HIV samples. Importantly, preincubation of uninfected MT2 cells with UC781 rendered these cells refractory to subsequent HIV infection in the absence of extracellular drug, an effect that persisted for several days following removal of exogenous drug. These unique properties of UC781 indicate that this nonnucleoside inhibitor may have considerable promise for use in retrovirucidal formulations to minimize the spread of HIV from infected to noninfected individuals.
Full Text
The Full Text of this article is available as a PDF (302.5 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Baba M., Pauwels R., Balzarini J., Arnout J., Desmyter J., De Clercq E. Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro. Proc Natl Acad Sci U S A. 1988 Aug;85(16):6132–6136. doi: 10.1073/pnas.85.16.6132. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bader J. P., McMahon J. B., Schultz R. J., Narayanan V. L., Pierce J. B., Harrison W. A., Weislow O. S., Midelfort C. F., Stinson S. F., Boyd M. R. Oxathiin carboxanilide, a potent inhibitor of human immunodeficiency virus reproduction. Proc Natl Acad Sci U S A. 1991 Aug 1;88(15):6740–6744. doi: 10.1073/pnas.88.15.6740. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Balzarini J., Brouwer W. G., Dao D. C., Osika E. M., De Clercq E. Identification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at a potency similar to that for wild-type virus. Antimicrob Agents Chemother. 1996 Jun;40(6):1454–1466. doi: 10.1128/aac.40.6.1454. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Connolly K. J., Hammer S. M. Antiretroviral therapy: reverse transcriptase inhibition. Antimicrob Agents Chemother. 1992 Feb;36(2):245–254. doi: 10.1128/aac.36.2.245. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fletcher R. S., Arion D., Borkow G., Wainberg M. A., Dmitrienko G. I., Parniak M. A. Synergistic inhibition of HIV-1 reverse transcriptase DNA polymerase activity and virus replication in vitro by combinations of carboxanilide nonnucleoside compounds. Biochemistry. 1995 Aug 15;34(32):10106–10112. doi: 10.1021/bi00032a002. [DOI] [PubMed] [Google Scholar]
- Fletcher R. S., Holleschak G., Nagy E., Arion D., Borkow G., Gu Z., Wainberg M. A., Parniak M. A. Single-step purification of recombinant wild-type and mutant HIV-1 reverse transcriptase. Protein Expr Purif. 1996 Feb;7(1):27–32. doi: 10.1006/prep.1996.0004. [DOI] [PubMed] [Google Scholar]
- Grob P. M., Wu J. C., Cohen K. A., Ingraham R. H., Shih C. K., Hargrave K. D., McTague T. L., Merluzzi V. J. Nonnucleoside inhibitors of HIV-1 reverse transcriptase: nevirapine as a prototype drug. AIDS Res Hum Retroviruses. 1992 Feb;8(2):145–152. doi: 10.1089/aid.1992.8.145. [DOI] [PubMed] [Google Scholar]
- Hirabayashi K., Iwata S., Ito M., Shigeta S., Narui T., Mori T., Shibata S. Inhibitory effect of a lichen polysaccharide sulfate, GE-3-S, on the replication of human immunodeficiency virus (HIV) in vitro. Chem Pharm Bull (Tokyo) 1989 Sep;37(9):2410–2412. doi: 10.1248/cpb.37.2410. [DOI] [PubMed] [Google Scholar]
- Johnson V. A. Combination therapy for HIV-1 infection-overview: preclinical and clinical analysis of antiretroviral combinations. Antiviral Res. 1996 Jan;29(1):35–39. doi: 10.1016/0166-3542(95)00912-4. [DOI] [PubMed] [Google Scholar]
- Levy J. A. Pathogenesis of human immunodeficiency virus infection. Microbiol Rev. 1993 Mar;57(1):183–289. doi: 10.1128/mr.57.1.183-289.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
- McMahon J. B., Buckheit R. W., Jr, Gulakowski R. J., Currens M. J., Vistica D. T., Shoemaker R. H., Stinson S. F., Russell J. D., Bader J. P., Narayanan V. L. Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor. J Pharmacol Exp Ther. 1996 Jan;276(1):298–305. [PubMed] [Google Scholar]
- Merluzzi V. J., Hargrave K. D., Labadia M., Grozinger K., Skoog M., Wu J. C., Shih C. K., Eckner K., Hattox S., Adams J. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science. 1990 Dec 7;250(4986):1411–1413. doi: 10.1126/science.1701568. [DOI] [PubMed] [Google Scholar]
- Merson M. H. Slowing the spread of HIV: agenda for the 1990s. Science. 1993 May 28;260(5112):1266–1268. doi: 10.1126/science.8493570. [DOI] [PubMed] [Google Scholar]
- Mitsuya H., Looney D. J., Kuno S., Ueno R., Wong-Staal F., Broder S. Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells. Science. 1988 Apr 29;240(4852):646–649. doi: 10.1126/science.2452480. [DOI] [PubMed] [Google Scholar]
- Moyle G., Gazzard B. Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs. 1996 May;51(5):701–712. doi: 10.2165/00003495-199651050-00001. [DOI] [PubMed] [Google Scholar]
- Neurath A. R., Jiang S., Strick N., Lin K., Li Y. Y., Debnath A. K. Bovine beta-lactoglobulin modified by 3-hydroxyphthalic anhydride blocks the CD4 cell receptor for HIV. Nat Med. 1996 Feb;2(2):230–234. doi: 10.1038/nm0296-230. [DOI] [PubMed] [Google Scholar]
- Niruthisard S., Roddy R. E., Chutivongse S. The effects of frequent nonoxynol-9 use on the vaginal and cervical mucosa. Sex Transm Dis. 1991 Jul-Sep;18(3):176–179. doi: 10.1097/00007435-199107000-00010. [DOI] [PubMed] [Google Scholar]
- Pauwels R., De Clercq E. Development of vaginal microbicides for the prevention of heterosexual transmission of HIV. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Mar 1;11(3):211–221. doi: 10.1097/00042560-199603010-00001. [DOI] [PubMed] [Google Scholar]
- Potts M. The urgent need for a vaginal microbicide in the prevention of HIV transmission. Am J Public Health. 1994 Jun;84(6):890–891. doi: 10.2105/ajph.84.6.890. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Roddy R. E., Cordero M., Cordero C., Fortney J. A. A dosing study of nonoxynol-9 and genital irritation. Int J STD AIDS. 1993 May-Jun;4(3):165–170. doi: 10.1177/095646249300400308. [DOI] [PubMed] [Google Scholar]
- Rooke R., Parniak M. A., Tremblay M., Soudeyns H., Li X. G., Gao Q., Yao X. J., Wainberg M. A. Biological comparison of wild-type and zidovudine-resistant isolates of human immunodeficiency virus type 1 from the same subjects: susceptibility and resistance to other drugs. Antimicrob Agents Chemother. 1991 May;35(5):988–991. doi: 10.1128/aac.35.5.988. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rooke R., Tremblay M., Wainberg M. A. AZT (zidovudine) may act postintegrationally to inhibit generation of HIV-1 progeny virus in chronically infected cells. Virology. 1990 May;176(1):205–215. doi: 10.1016/0042-6822(90)90245-m. [DOI] [PubMed] [Google Scholar]
- Szedlacsek S. E., Duggleby R. G. Kinetics of slow and tight-binding inhibitors. Methods Enzymol. 1995;249:144–180. doi: 10.1016/0076-6879(95)49034-5. [DOI] [PubMed] [Google Scholar]
- Williams J. W., Morrison J. F. The kinetics of reversible tight-binding inhibition. Methods Enzymol. 1979;63:437–467. doi: 10.1016/0076-6879(79)63019-7. [DOI] [PubMed] [Google Scholar]
- Yao X. J., Wainberg M. A., Parniak M. A. Mechanism of inhibition of HIV-1 infection in vitro by purified extract of Prunella vulgaris. Virology. 1992 Mar;187(1):56–62. doi: 10.1016/0042-6822(92)90294-y. [DOI] [PubMed] [Google Scholar]
- Zhang H., Dornadula G., Pomerantz R. J. Endogenous reverse transcription of human immunodeficiency virus type 1 in physiological microenviroments: an important stage for viral infection of nondividing cells. J Virol. 1996 May;70(5):2809–2824. doi: 10.1128/jvi.70.5.2809-2824.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zhang H., Zhang Y., Spicer T. P., Abbott L. Z., Abbott M., Poiesz B. J. Reverse transcription takes place within extracellular HIV-1 virions: potential biological significance. AIDS Res Hum Retroviruses. 1993 Dec;9(12):1287–1296. doi: 10.1089/aid.1993.9.1287. [DOI] [PubMed] [Google Scholar]